News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Deridre Kelly: Ph2 Capmatinib in METex14 NSCLC
Photo taken from Deridre Kelly/X
Oct 4, 2024, 09:43

Deridre Kelly: Ph2 Capmatinib in METex14 NSCLC

Deridre Kelly, Professor of Paediatric Hepatology at the University of Birmingham, sharen on X:

“New The Lancet Oncology – Phase2 Capmatinib in METex14 NSCLC

 Objective response rate: 68%

 Progression-free survival: 12.5 months

 Overall survival: 21.4 months (1st-line), 16.8 months (later lines)

 Adverse Events: edema 47%, nausea 35%, creatinine 21%, vomiting 20%

METex14 key biomarker for METi.”

Source: Deridre Kelly/X

adverse events cancer capmatinib creatinine Deridre Kelly edema Key biomarkers METex14 METi nausea NSCLC objective response rate OncoDaily Oncology Overall survival (OS) progression-free survival The Lancet Oncology vomiting
Special Coverage
Blog
Dec 21, 2024, 11:30
Kyaw Thein: Tissue-Agnostic Drug Development in Cancer
Dialogues
Dec 21, 2024, 11:29
Beyond the Cancer Diagnosis: Dialogue with Marianne Arab, Hosted by Adrian Pogacian
Blog
Dec 21, 2024, 11:27
Aleix Prat: Carlos Fernandez de Larrea has been appointed as a Professor at the University of Barcelona
Blog
Dec 21, 2024, 11:25
Canadian Cancer Society - Natalie Wild's caregiver story
Blog
Dec 21, 2024, 11:24
Christy Brown: How many things can you dread more than 'your child has aggressive brain cancer?'
Blog
Dec 21, 2024, 11:18
Jose Fernando Moura: Pivotal SABCS24 summary hosted by Cancer Network
Blog
Dec 21, 2024, 11:18
Jérôme Salomon: President Macron, WHO Director-General and global health leaders inaugurate WHO Academy
Blog
Dec 21, 2024, 11:17
ChatGPT-Like AI Tool Promises to Speed Treatment Advances and Free Doctors’ Time by Matching Patients with Clinical Trials
Blog
Dec 21, 2024, 11:14
Mediamedic - Wenbin Zhou on Pyrotinib-based regimen in HER2-positive breast cancer
Blog
Dec 21, 2024, 11:12
Didier Verhoeven: Comparing survival in breast cancer in Belgian Breast Centres
Blog
Dec 21, 2024, 11:06
Every great journey has its finale - eCAN Joint Action
Drugs
Dec 21, 2024, 10:38
Hanna Foster: Market cap and Revenue of Cancer NGS Drugs providers in 2024